Championing the Missions that Matter™
Catalent is a global end-to-end Contract Development and Manufacturing Organization (CDMO), trusted by pharma, biotech and self-care companies to accelerate the development, manufacturing and delivery of products that improve lives.
With advanced technologies, deep expertise and a worldwide network, we partner with innovators to transform bold ideas into life-changing therapies and self-care solutions.
0B
Doses delivered annually across global markets
0+
Active development projects driving health innovation
We partner with innovators to help people live better & healthier lives
Our mission is to develop, manufacture and supply products that help people live better and healthier lives.
Our people are committed to improving health outcomes worldwide. From every therapy we develop to every product we help manufacture and launch, we put patients and consumers first.
With global expertise, advanced technologies and a seamless network, our self-care and pharma solutions deliver the results our partners need, reliably and at scale.
Service Built Around Your Goals
We collaboratively work with innovators in pharma and biotech to enhance patients' lives.
Our integrated CDMO pharma solutions span small molecules, biologics, cell and gene therapies (CGT) and clinical supply, all supported by advanced technologies, global scale and proven expertise.
From early-stage design to commercial manufacturing, we deliver seamless tech transfers, reliable outcomes and the highest standards of quality as we help bring your mission to life.
We partner with health and wellness brands to turn innovation into everyday impact.
With pharma-grade expertise, consumer insight and versatile dosage forms, we help deliver products that people trust—fast, safe and effective.
Supported by global scale and integrated solutions, we make it easier for consumers to take charge of their well-being and live healthier lives.
Why Catalent?
Our Patient-first approach guides every decision as we deliver tailored pharma solutions at global scale. Together, our scientific, technical and manufacturing experts deliver more than 60 billion doses of life-enhancing and life-saving treatments annually.
Your mission stays central, supported by deep development expertise and unparalleled service. Over the past decade, we have assisted in half of all FDA approvals, helping products reach the people who need them.
Global Footprint
With nearly 40 sites worldwide, we support development, manufacturing and supply across regions with consistent quality systems and local expertise.
Insights & Expertise
Access expert guidance and industry resources from scientific and commercial leaders to bring your self-care and pharma solutions to market faster.
Complex Proteins. Lightning Speed.
Discover how Catalent advances bispecifics, multispecifics and other complex multichain molecules from gene sequence to released GMP drug substance in an anticipated 10 months, powered by GPEx® Lightning™ cell line development and one coordinated, U.S.-based program.
GPEx® Lightning™: Tunable Expression and an Integrated PD Toolbox for Multispecific Antibody Delivery
Bispecific and multispecific biologics present distinct development challenges, including imbalanced chain expression, product-related impurities, and complex purification requirements. This whitepaper demonstrates how Catalent’s GPEx® Lightning™ technology enables tunable multi-chain expression by
European Early Phase CDMO Solutions
Catalent’s European Early Phase CDMO network provides integrated formulation development, analytical testing, clinical manufacturing, packaging, and supply solutions designed to accelerate molecules from preclinical development through Phase II and beyond. By connecting specialized Centers of Excell
Bringing Clinical Trials Closer to Patients
Bring clinical trials closer to patients with flexible direct-to-patient, site-to-patient, and hybrid delivery models. Catalent's FlexDirect® service helps improve patient access, support recruitment and retention, and simplify trial logistics through global programme management and integrated clini
